Please login to the form below

Not currently logged in
Email:
Password:

Eisai/ UCL partnership grows

Eisai is to extend its partnership with University College London, a UK-based university with which the company has been collaborating with for more than 20 years

Eisai is to extend its partnership with University College London (UCL), a UK-based university with which the company has been collaborating with for more than 20 years.

The new phase will see the Eisai and UCL engage in joint research in neurodegenerative disease including biomarker research into neuroinflammation, neurovascular/mitochondria and proteostasis.

During the course of their partnership which began in 1990, Eisai and UCL established an Eisai research facility on the UCL campus and have forged strong co-operative ties through research activities that included the exchange of personnel.

Additionally Eisai said it plans to submit marketing authorisation applications to the regulatory authorities in the US and Europe for perampanel, a first-in-class, highly selective, non-competitive AMPA-type glutamate receptor antagonist that was created through collaborative with UCL research, to complement its marketed products which include Zonegran (zonisamide), Inovelon (rufinamide) and Zebinix (eslicarbazepine acetate).

26th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...